source
- Biopharma pay series to return with new installmentsThe publisher announced that new installments of its biopharma pay series will be released in the near future. The series traditionally examines compensation trends and salary data across the phar…
- Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effectsBoehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…